CN Patent

CN120535504A — 一种p38α-MK2抑制剂的晶型及其制备方法和应用

Assigned to Changchun Genescience Pharmaceutical Co Ltd · Expires 2025-08-26 · 1y expired

What this patent protects

本发明提供了式(I)所示化合物的无定型或多晶型物，所述无定型和多晶型物具有优异的稳定性，适合产业上的生产制造保存。

USPTO Abstract

本发明提供了式(I)所示化合物的无定型或多晶型物，所述无定型和多晶型物具有优异的稳定性，适合产业上的生产制造保存。

Drugs covered by this patent

Rezlidhia (OLUTASIDENIB) · Rigel Pharms

Patent Metadata

Patent number: CN120535504A
Jurisdiction: CN
Classification: —
Expires: 2025-08-26
Drug substance claim: No
Drug product claim: No
Assignee: Changchun Genescience Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.